LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Kodu・Aktsiate loetelu・Pulse Biosciences Inc

Pulse Biosciences Inc

Avatud

SektorTervishoid

13.7 -0.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.56

Max

13.96

Põhinäitajad
By Trading Economics
Sissetulek	-217K -19M
Müük	86K 86K
Aktsiakasum	-0.29
Kasumimarginaal	-22,540.698
Töötajad	75
EBITDA	-228K -19M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+59.54% upside

Turustatistika
By TradingEconomics
Turukapital	-179M 958M
Eelmine avamishind	14.14
Eelmine sulgemishind	13.7

Uudiste sentiment

By Acuity

50%

168 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

16.59 / 17.17 Toetus ja vastupanu

Pulse Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. nov 2025, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27. nov 2025, 15:32 UTC

Omandamised, ülevõtmised, äriostud

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27. nov 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27. nov 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. nov 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27. nov 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27. nov 2025, 15:54 UTC

Omandamised, ülevõtmised, äriostud

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27. nov 2025, 15:44 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27. nov 2025, 15:43 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27. nov 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27. nov 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27. nov 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27. nov 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27. nov 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27. nov 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. nov 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27. nov 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27. nov 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27. nov 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27. nov 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27. nov 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27. nov 2025, 11:07 UTC

Tulu

Genting: Positive About Prospects Over Longer Term

27. nov 2025, 11:06 UTC

Tulu

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27. nov 2025, 11:04 UTC

Tulu

Genting: International Travel Demand Expected to Remain Resilient

27. nov 2025, 11:04 UTC

Tulu

Genting: Global Growth Expected to Remain Subdued

27. nov 2025, 11:04 UTC

Tulu

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27. nov 2025, 10:59 UTC

Tulu

Genting Bhd 3Q Net Profit Fell 86% on Year

27. nov 2025, 10:58 UTC

Tulu

Genting Bhd 3Q Rev Rose 14% on Year

27. nov 2025, 10:56 UTC

Tulu

Genting Bhd 3Q Net MYR30.3M

27. nov 2025, 10:56 UTC

Tulu

Genting Bhd 3Q EPS MYR0.0079

Võrdlus sarnastega

Hinnamuutus

Pulse Biosciences Inc Prognoos

Hinnasiht

By TipRanks

59.54% tõus

12 kuu keskmine prognoos

Keskmine 22 USD 59.54%

Kõrge 22 USD

Madal 22 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Pulse Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pulse Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

16.59 / 17.17Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

168 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.